期刊文献+

Cystatin C在评价慢性肾病患者肾小球滤过功能中的作用 被引量:10

Effect of Cystatin C on evaluation of glomerular filtration function in chronic kidney disease patients
下载PDF
导出
摘要 目的:比较血清半胱氨酸蛋白酶抑制剂C(Cystatin C)、肌酐(Scr)、肌酐清除率(Ccr)在慢性肾病(CKD)患者各期与估算的肾小球滤过率(eGFR)的符合率。方法:血清Cystatin C采用免疫透射比浊法测定,Scr和尿肌酐采用酶法测定,基于Scr估算的eGFR采用MDRD方程进行计算,CKD患者根据1999年美国肾病基金会(NKF)公布的K/DOQI指南按eGFR分为5期。结果:168例CKD患者各期Cystatin C,Scr随eGFR的降低而逐渐升高,Ccr随eGFR的降低而逐渐降低,三者在各期间水平的差异均有统计学意义(P〈0.05)。当eGFR≤29 ml/min时,Cystatin C,Scr,Ccr的异常率均为100%,Cystatin C,Scr平均水平是正常参考上限的3~5倍和4~6倍,Ccr下降4~7倍,三者呈平行性改变;在eGFR 30~59 ml/min组,Cystatin C,Scr,Ccr的平均水平分别为2.06 mg/L,131.2μmol/L和45.6 ml/min,异常率分别为97%,80%和89%,三者之间异常率的差异无统计学意义(P〉0.05);在eGFR 60~89 ml/min组,Cys-tatinC,Ccr异常率为87%和69%,Scr异常率为6.5%,三者之间异常率的差异具有统计学意义(P〈0.05);在eGFR≥90 ml/min组,Cystatin C,Ccr异常率为60%和42%,Scr异常率为0。结论:eGFR〈60 ml/min时,其与Cystatin C,Scr,Ccr的总符合率高,基本可以诊断肾小球滤过功能中度下降;60 ml/min≤eGFR≤89 ml/min时,Cystatin C,Ccr可以检出2/3患者肾小球滤过率的异常,Cystatin C比Ccr更敏感,而Scr不能反应肾小球滤过功能的下降;当eGFR≥90 ml/min时,MDRD方程高估了实际GFR,对于老年CKD患者,MDRD方程不适用,需检测Cystatin C和Ccr以及时发现GFR的下降。 Objective: To compare the coincidence of Cystatin C, serum creatinine,creatinine clearance (Ccr) in each eGFR stage of chronic kidney disease(CKD) patients. Methods: Cystatin C was measured by turbidimetric method, Creatinine in serum and urine were determined by enzyme method, while eGFR was calculated using the abbreviated MDRD equation which was mainly based on the serum creatinine concentration. According to the American NKF-K/DOQI guideline, all cases were grouped by eGFR into 5 stages. Results: In these 168 cases, as eGFR decreased gradually, the average levels of Cystatin C and creatinine increased, while Ccr decreased. The level of each items showed a statistic difference among each stage(P 〈0.05 ), in eGFR 429 ml/min groups, the abnormal rate of Cystatin C, Scr, Ccr were all 100% , and the average levels of Cystatin C and Scr were 3 -6 times and 4 -5 times to the upper reference limit, while Ccr was 4 -7 times to the lower reference limit; in eGFR 30 -59 ml/min groups, the average levels of Cystatin C, Scr and Ccr were 2.06 mg,/L, 131.2 μmol/L and 45.6 ml/min, and the abnormal rate were 97% , 80% and 89% respectively,no statistic difference was observed among the three rates (P 〉 0.05 ) ; in eGFR 60 - 89 ml/min groups, the level of Cystatin C and Ccr showed a marginal increase and decrease, with an abnormal rates of 87% and 69% , the abnormal rate of Scr was 6.5% , there was a statistic difference among the three abnormal rates(P 〈 0.05 ) ; when eGFR ≥90 ml/min, the abnormal rates of Cystatin C and Ccr reached to 60% and 42%, while the abnormal rate of Scr was 0, respectively. Conclusion: when eGFR was less than 60 ml/min, it showed a good coincidence with Cystatin C, Scr and Ccr, at this time a conclusion could be drown that glomeruler filtration function had decreased moderately; when it was 60 ml/min≤eGFR≤89 ml/min, Cystatin C and Ccr could at least select out 2/3 patients with abnormal GFR, but Scr could not reflect the damage on GFR, and Cystatin C was more s
出处 《江苏大学学报(医学版)》 CAS 2008年第4期348-350,355,共4页 Journal of Jiangsu University:Medicine Edition
关键词 半胱氨酸蛋白酶抑制剂 肌酐 肌酐清除率 肾病 cysteine proteinase inhibitors creatinine creatinine clearance nephrosis
  • 相关文献

参考文献5

二级参考文献30

  • 1李海霞,张春丽,徐国宾,王学晶,李淑葵,李志艳,张旭初,夏铁安.健康人群血清半胱氨酸蛋白酶抑制剂C与肌酐分布及其评价慢性肾脏病患者肾小球滤过功能的比较研究[J].中华检验医学杂志,2006,29(11):970-974. 被引量:179
  • 2Garg AX, Kiberd BA, Clark WF, et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES Ⅲ.Kidney Int,2002,61:2165-2175. 被引量:1
  • 3Ramirez SP, Mcclellan W, Port FK, et al. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol, 2002,13 : 1907-1917. 被引量:1
  • 4Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am J Kidney Dis,2003,41:1-12. 被引量:1
  • 5Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study.J Am Soc Nephrol,2003,14:s131-s138. 被引量:1
  • 6Iseki K, Jseki C, Ikemiya Y, et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int, 1996,49:800-805. 被引量:1
  • 7Li PK, Kwan BC, Leung CB, et al. Prevalence of silent kidney disease in Hong Kong: The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney Int Suppl,2005,94 :s36-40. 被引量:1
  • 8Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement : a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem, 2006,52:5-18. 被引量:1
  • 9Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glonlerular filtration rate. N Engl J Med ,2006,354:2473-2483. 被引量:1
  • 10Cockcruft DW, Gault MH. Prediction of ereatinine clearance from serum creatinine. Nephron, 1976,16:31-41. 被引量:1

共引文献248

同被引文献51

引证文献10

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部